Izquierdo, 19,208 patient N-acetylcysteine late treatment study: 26% lower mortality [p=0.0007] https://c19p.org/izquierdo
copied to clipboard
Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19
et al., Science Progress, doi:10.1177/00368504221074574
Retrospective 19,208 COVID+ hospitalized patients in Spain, 2,071 treated with high dose NAC, showing lower mortality with treatment. In multivariable analysis, authors adjust for corticosteroids, but do not adjust for HCQ use which was also significantly more common in the NAC group. NAC 600mg every 8 hours.
|
risk of death, 25.6% lower, RR 0.74, p < 0.001, treatment 136 of 2,071 (6.6%), control 1,935 of 17,137 (11.3%), adjusted per study, odds ratio converted to relative risk, multivariable.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
significant unadjusted confounding possible.
Izquierdo et al., 1/27/2022, retrospective, Spain, Europe, peer-reviewed, 7 authors, study period 1 March, 2020 - 24 January, 2021.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.